| Systematic (IUPAC) name | |
|---|---|
| Ethyl ([(7S)-7-([(2R)-2-(3-chlorophenyl)-2-hydroxyethyl]amino)-5,6,7,8-tetrahydronaphthalen-2-yl]oxy)acetate | |
| Clinical data | |
| Pregnancy cat. | ? |
| Legal status | ? |
| Identifiers | |
| CAS number | 121524-09-2 |
| ATC code | None |
| PubChem | CID 3035442 |
| IUPHAR ligand | 568 |
| ChemSpider | 108738 |
| UNII | PDQ3ME68U3 |
| KEGG | D08851 |
| ChEMBL | CHEMBL545437 |
| Chemical data | |
| Formula | C22H26ClNO4 |
| Mol. mass | 403.898 g/mol |
| SMILES | eMolecules & PubChem |
|
|
| |
|
Amibegron (SR-58,611A) is a drug developed by Sanofi-Aventis which acts as a selective agonist for the β3 adrenergic receptor. It is the first orally active β3 agonist developed that is capable of entering the Central Nervous System, and has antidepressant and anxiolytic effects.[1][2]
On July 31, 2008, Sanofi-Aventis announced that it has decided to discontinue development of amibegron.[3]
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| This drug article relating to the nervous system is a stub. You can help Wikipedia by expanding it. |
This entry is from Wikipedia, the leading user-contributed encyclopedia. It may not have been reviewed by professional editors (see full disclaimer)